Giving lignocaine intravenously for upper limb surgeries
Phase 2
- Conditions
- Health Condition 1: M959- Acquired deformity of musculoskeletal system, unspecifiedHealth Condition 2: M958- Other specified acquired deformities of musculoskeletal system
- Registration Number
- CTRI/2023/11/059549
- Lead Sponsor
- Dr Kiran A V
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients who are posted for elective upper limb surgeries lasting <1hour.
ASA I and II
Patients giving informed written consent.
Exclusion Criteria
Patients with coagultaion disoders sickle cell disease raynauds disease.
Morbidly obese patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sensory and motor effects of magnesium sulphate versus clonidine when added to lignocaine in intravenous regional anesthesia for upper limb surgeriesTimepoint: 1 Year
- Secondary Outcome Measures
Name Time Method To compare the duration of post operative analgesia and frequency of rescue analgesic requirement after addition of magnesium sulphate versus clonidine to lignocaine. <br/ ><br>To describe any side effects of magnesium sulphate and clonidine.Timepoint: 24 hours